0.290
+0.010
(3.57%)
May 17 - Close
OTCMKTS
data delayed by 15 mins -
Disclaimer
Currency in USD
| Range | 0.26 - 0.30 |
| 52 week | 0.18 - 0.92 |
| Open | 0.27 |
| Vol / Avg. | 26,853.00/37,949.00 |
| Mkt cap | 4.75M |
| P/E | - |
| Div/yield | - |
| EPS | -2.62 |
| Shares | 16.37M |
| Beta | 1.24 |
| Inst. own | 5% |
Key stats and ratios
| Q3 (Sep '12) | 2011 | |
| Net profit margin | -158.23% | -1315.92% |
| Operating margin | -144.57% | -1565.07% |
| EBITD margin | - | -729.87% |
| Return on average assets | -77.14% | -142.86% |
| Return on average equity | - | -342.00% |
| Employees | 11 | - |
| Carbon Disclosure Rating | - | - |
Address
Website links
External links
Discussion Group - Google Finance
Advertisement
Description
Marina Biotech, Inc. is a biotechnology company focused on the discovery, development and commercialization of nucleic acid-based therapies utilizing gene silencing approaches such as RNA interference (RNAi) and blocking messenger RNA (mRNA) translation. The Company's pipeline includes a clinical program in Familial Adenomatous Polyposis (FAP) and preclinical programs in bladder cancer and myotonic dystrophy. The Company has two liposomal-based delivery platforms. The first platform utilizes amino-based liposomal delivery technology and incorporates a molecule the Company calls DiLA2 (Di-Alkylated Amino Acid). In April 2012, the Company announced the completion of dosing for Cohort 2 in the Dose Escalation Phase of the START-FAP (Safety and Tolerability of An RNAi Therapeutic in Familial Adenomatous Polyposis) clinical trial of CEQ508.
Officers and directors
| J. Michael French | Chairman of the Board, President, Chief Executive Officer | |
| Philip C. Ranker | Interim Chief Financial Officer, Secretary | |
| Richard T. Ho M.D., Ph.D. | Executive Vice President - Research and Development | |
| Stefan D. Loren Ph.D. | Lead Independent Director | |
| Joseph W. Ramelli | Independent Director |
